A B S T R A C T GSH plays an important role in cellular defense against a wide variety of toxic electrophiles via the formation of thioether conjugates. We studied the role of GSH in murine tumor cell defense against a novel class of sulfhydryl-reactive antineoplastics, the sesquiterpene lactones (SL). Incubation of P815 mastocytoma cells with any of the four SL tested (vernolepin, helenalin, elephantopin, and eriofertopin) for 1 h resulted in 70-97% depletion of GSH. The importance of GSH resynthesis upon exposure of tumor cells to SL was evaluated with the use of buthionine sulfoximine (BSO), a selective, nontoxic inhibitor of y-glutamylcysteine synthetase. Inhibition of GSH synthesis with 0.2 mM BSO markedly enhanced SL-mediated cytolysis of four murine tumor cell lines. A 6-to 34-fold reduction in the amount of SL causing 50% lysis was obtained with BSO. Addition of BSO to P815 cells either during or immediately after a 1-h pulse with 10 ug/ml of vernolepin increased cytolysis from <3% to 78-82%. However, a 1.5-h delay in the addition of BSO to such cells, which allowed for substantial resynthesis of GSH, reduced cytolysis to 30%. Recovery of GSH synthetic capacity after BSO treatment correlated with loss of the synergistic effect of BSO on lysis by vernolepin. BSO did not augment cytolysis by six other antineoplastics (doxorubicin, mitomycin C, vinblastine, cytosine arabinoside, maytansine, and 1,3-bis-[2-chloroethyl]-1-nitrosourea [BCNU] 
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INTRODUCTION
Glutathione, the most abundant nonprotein sulfhydryl of mammalian cells, has been shown to play a critical role in cellular defense against a variety of injurious agents (1-3). We have previously studied the role of the GSH redox cycle in tumor cell defense against oxidative injury. In those studies, interference with the GSH redox cycle augmented in vitro cytolysis of tumor cells by macrophages and granulocytes as well as by a model H202-delivery system (glucose oxidase plus glucose) (4, 5) . Similar manipulations enhanced the antitumor activity of H202 in vivo (6) . GSH also plays a role in protection against toxic electrophiles by thioether formation. In contrast to the cyclic oxidationreduction of GSH during antioxidant defense, restoration of GSH content after detoxification of electrophiles is dependent upon its resynthesis. In this report, we consider the role of GSH and its synthesis in tumor cell defense against sulfhydryl-reactive antineoplastics, in particular, the sesquiterpene lactones (SL).' SL are among the natural products that have attracted attention recently as prototypes for the development of novel chemotherapeutic agents (7) (8) (9) (10) (11) . Some SL inhibit cell growth in vitro, and at higher concentrations, lead to cell death (12) (13) (14) (15) (16) . High reactivity towards sulfhydryl groups in aqueous buffer is a characteristic feature of SL (17) (18) (19) (20) , and has led to the hypothesis that their antitumor activity is the result of S-alkylation of growth-regulatory or otherwise vital macromolecules (8, 18, 21, 22) . Several sulfhydryl-dependent enzymes have been shown to be inhibited by these agents (19, (23) (24) (25) . Nonetheless, the cellular targets relevant to their antitumor activity in vitro or in vivo have not been identified. Furthermore, it has not been reported whether SL are reactive towards sulfhydryl groups in intact cells.
We studied four SL that are active in vitro (vernolepin, helenalin, elephantopin, and eriofertopin, Fig. 1 Tumors. P815 mastocytoma, YAC-1 lymphoma, and TLX9 lymphoma tumors were maintained by intraperitoneal passage of ascites in histocompatible mice as described (4, 27) . For experiments, these tumors were grown in stationary suspension cultures in MEM, supplemented with 100 ,ug/ml of streptomycin, 100 U/ml penicillin, and 10% heat- Glutathione depletion. Tumor cells in MEM, 5% horse serum (1.0 X 10' -1.7 X 106/ml) were incubated at 37°C with the various test compounds dissolved in dimethyl sulfoxide, or vehicle alone, for the indicated times. Dimethyl sulfoxide content ranged from 0.1 to 1% and did not affect GSH levels.
Biochemical assays. Total cellular glutathione (GSH plus GSSG) was measured by a minor modification of the method of Tietze as previously described (5, 28) . Total glutathione is expressed as nanomoles of the tripeptide per milligram of cell protein and is referred to as GSH in this report. Extracts of cells treated with compounds that we found to cause GSH depletion were mixed with known amounts of GSH and then assayed to rule out the presence of an inhibitor of the Tietze assay, which might have accounted for the observed loss of GSH. The activity of glucose oxidase was measured with the scopoletin assay for H202 as described (29) . Glutathione reductase was assayed by the method of Roos et al. (30) . Protein content was determined by the method of Lowry et al. (31) using bovine serum albumin as the standard.
Inhibition of glutathione synthesis with BSO. We have previously reported that with these tumors a maximal rate of GSH depletion, and thus maximal inhibition of synthesis, was achieved with 0.2 mM BSO (5). The rate of GSH depletion in the presence of BSO reflects GSH catabolism, efflux, and dilution by cell division in the absence of synthesis. BSO stock solution (20 mM in H20) was stored at 0°C for up to 3 wk before use.
Cytolysis assays. Cells were labeled with Na251CrO4 as described (27) At the indicated times (18 h for a and b, 5 h for c), supernatant (0.1 ml for a and c, 0.5 ml for b) was removed after centrifugation for gamma counting and the percent specific release was calculated as described (27) . The amount of lytic agent causing 50% specific release of 51Cr label (LD50) was determined from a dose-response curve by interpolation. In protocol b, if 51Cr release was measured after 26 h rather than 18 h, the LD50 was reduced by a factor of 1.2 while the spontaneous release increased by a factor of 1.4 . In some experiments the 51Cr release assay was validated by comparison to the trypan blue dye exclusion test as described (4) . Each reported data point represents the mean of triplicate determinations.
RESULTS
Depletion of tumor cell GSH by SL. The possible interaction of cellular GSH with SL was first evaluated. Incubation of P815 mastocytoma cells with vernolepin, helenalin, elephantopin, or eriofertopin for 1 h resulted in 70-97% depletion of GSH (Table I ). The time course and dose response of GSH depletion by helenalin were examined in greater detail in the experiments illustrated in Fig. 2 . Cells were incubated with a range of concentrations of helenalin with and without 0.2 mM BSO, a nontoxic and selective inhibitor of the first of two enzymes responsible for GSH biosynthesis, y-glutamylcysteine synthetase (26) . P815 cells incubated with BSO remain viable (5) , and continue to divide in its presence for more than 3 wk (unpublished observations). Depletion of GSH by incubation of P815 cells with 25 sg/ml of helenalin was both rapid (90% loss within 15 min) and persistent (up to 7 h of coincubation) ( Fig. 2A) . Incubation of cells with 1 jsg/ ml of helenalin did not result in detectable GSH depletion. However, the rate of GSH depletion upon incubation with 1 jg/ml of helenalin plus BSO exceeded that observed with BSO alone (Fig. 2B) . By inference, 1 lAg/ml of helenalin must react with a substantial portion of intracellular GSH, and rapid resynthesis, if unimpeded, maintains GSH content at normal levels. Similarly, the recovery of GSH levels observed with 5 ug/ml of helenalin was abolished by the inclusion of BSO (Fig. 2, closed triangles) . By examination of the medium after incubation of cells with helenalin, we determined that depletion of GSH was not due to its release from the cells (not shown).
Effect of BSO on the lysis of tumor cells by SL. We evaluated the sensitivity of 51Cr-labeled tumor cells to lysis by an 18-h coincubation with SL. Fig. 3 illustrates one such experiment in which the lysis of P815 cells by helenalin in the presence or absence of 0.2 mM BSO was measured. Incubation of tumor cells with BSO alone was nontoxic. However, cytolysis by helenalin was greatly enhanced: nonlytic concentrations of helenalin resulted in near-complete lysis when BSO was included (Fig. 3) . In Fig. 3 , BSO reduced the LDNj for helenalin by a factor of 4.7. The effect of BSO on the sensitivity of four tumor cell lines to lysis by SL is documented in Table II . In each experiment, a range of SL concentrations was tested and the LD50 was calculated as in Fig. 3 . In all cases, the presence of BSO most dramatic synergy with vernolepin, leading to an -20-fold decrease in the LD50 for P815. It is of interest to note that for these tumors, the rank order of resistance to lysis by vernolepin (J774 > P815 > TLX9 > YAC) does not correspond to GSH content (J774 > YAC > P815 > TLX9) (4) . Furthermore, incubation of P815 cells with 10 jg/ml of vernolepin for 1 h before the 18-h assay did not result in increased cytolysis (not shown), in spite of substantial depletion of GSH (>90% in Table I ). Thus, in contrast to the importance of GSH resynthesis in protecting tumor cells upon exposure to SL, GSH content prior to exposure to these agents did not influence subsequent lysis.
The synergistic interaction between BSO and vernolepin was further analyzed by considering the kinetics of onset and reversal of their effects. For this, exposure of cells to vernolepin was limited to a 1-h pulse, followed by an 18-h incubation in its absence, at which time lysis was determined. Fig. 4 ,gg/ml); during this time as well as the subsequent 18- h incubation (closed circles, LD50 = 6.8 ,ug/ml); or during the 18-h incubation only (closed triangles, LD50 = 13.8,ug/ml). Thus, addition of BSO need not coincide with but can immediately follow exposure to vernolepin for markedly enhanced cytolysis to result.
Time course of recovery from the effects of vernolepin and BSO. Fig. 5 illustrates the correlation between GSH resynthesis and loss of tumor cell sensitivity to the synergistic effect of BSO added after a 1-h pulse of vernolepin. Recovery of GSH content upon subsequent incubation was rapid, reaching control levels by 3.5 h. Recovery of GSH content could be inhibited by BSO, indicating that de novo resynthesis was occurring. A 1.5-h delay in the addition of BSO to cells previously pulsed for 1 h with 10 sg/ml of vernolepin allowed for resynthesis of GSH to -60% of control, and resulted in roughly a 60% decrease in enhancement of cytolysis, compared to the addition of BSO immediately after the vernolepin pulse. The marked cytolysis observed by treatment of cells with 10 ,g/ml of vernolepin followed by an 18-h incubation with BSO was not prevented by the addition of up to 7 mM GSH to the medium shortly after the start of the 18-h incubation (not shown). (Fig. 6A) . Similarly, -3 h after a 1-h incubation with BSO, cells began rapidly to recover their resistance to the cytolytic effect of vernolepin (Fig. 6B) . Thus, augmentation by BSO of susceptibility to lysis by vernolepin disappeared just as the tumor cells regained their capacity to synthesize GSH. Addition of cycloheximide (10 Ag/ml) after removal of BSO did not inhibit recovery, indicating that synthesis of new y-glutamylcysteine synthetase was not required in order to reverse the effects of BSO (not shown). GSH depletion by other antitumor agents and the effect of BSO on cytolysis by these agents. We were interested in extending our observations to a variety of antitumor agents, with and without known sulfhydryl reactivity. Many antitumor agents recently de-' rived from plants, in addition to the cytotoxic sesquijatrophone (not shown).
In a similar manner, we studied six other antitumor agents chosen from three major classes of antineoplastics (alkylating agents, anti-metabolites, and natural products). The effects of these compounds on the GSH content of P815 cells, using a 1-h incubation at 5 Correlation between the rate of GSH resynthesis after a 1-h incubation with vernolepin and the loss over time of synergistic cytolysis when BSO was added after the vernolepin pulse. In the cytolysis assay, cells were pulsed with 10 /Lg/ml of vernolepin for 1 concentrations that would be lytic in an 18-h assay, are documented in Table III . Of these, only BCNU was able significantly to reduce the GSH content of the cells. However, unlike jatrophone or SL, cytolysis by BCNU after an 18-h incubation was not affected by the presence of BSO (Table III) . The lack of an effect of BSO on cytolysis by the other five agents correlated with their inability to deplete cellular GSH (Table III) .
Effect of vernolepin on susceptibility of P815 cells to oxidative cytolysis. Inhibition of the GSH redox cycle sensitizes tumor cells to lysis by H202 (4, 5) . It was therefore of interest to evaluate the effect of vernolepin on lysis of P815 cells by a flux of H202 generated by the addition of glucose oxidase to the glucose-containing medium. In one such experiment (Fig.  8A) , H202-mediated lysis at 5 h was markedly enhanced in the presence of 10 jtg/ml of vernolepin. Fig.   8B illustrates the dose-response of vernolepin-induced sensitization to glucose oxidase-mediated cytolysis. A >6.5-fold increase in susceptibility to lysis by H202 was achieved with 20 ug/ml of vernolepin (Fig. 8B) . Addition of BSO together with the indicated concentrations of vernolepin served to enhance even further the oxidative lysis of these cells (Fig. 8B) . Inclusion of BSO alone was without effect (Fig. 8A) (36) , L-phenylalanine mustards (37, 38) , nitrosoureas (4, 39) , doxorubicin (39) (40) (41) (42) , hydrogen peroxide (4-6), and y-irradiation (43, 44) .
Incubation of P815 mastocytoma cells with any of the four SL studied (vernolepin, helenalin, elephantopin, and eriofertopin) resulted in rapid, dose-dependent depletion of GSH, presumably via adduct formation. Comparison of the rate of GSH depletion by low concentrations of helenalin (1-5 ,ug/ml) in the presence of BSO, a nontoxic and selective inhibitor of 'y-glutamylcysteine synthetase, with that observed with BSO alone or helenalin alone, suggests that a compensatory increase in the rate of GSH synthesis is an early cellular response to these agents.
We evaluated the dose-response of SL-mediated cytolysis, in the presence or absence of BSO, by measurement of 5"Cr released after an 18-h coincubation. Incubation of P815 cells with BSO and the resulting depletion of GSH, was without effect on their viability or even their growth (5 be without consern of GSH by BCNU
